Companies: 10,795·Total market cap: $144.5T
Humacyte, Inc.

Humacyte, Inc.

HUMANASDAQHealthcare● Active
$1.40
+$0.05(+3.70%)
Market Cap$235199996
P/E Ratio
52W High$2.93
52W Low$0.547
Overview

Humacyte, Inc. (HUMA) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

huma · stock forecast · 11 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 11 Wall Street analysts in the past 3 months

SellBuy

Buy

11 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
10
Hold
1
Sell
0
Strong Sell
0
Total: 11 · Buy rate: 90.9%

12-Month Price Target

High

$10.00

Consensus

$5.58

+300.0% upside

Low

$3.00

Median: $5.5 · Last Close: $1.40

The Humacyte, Inc. (HUMA) analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month HUMA price target is $5.58, representing +300.0% upside from the current price of $1.40.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $6 (300.0%)

Consensus Target

$5.58

300.0% upside

High Target

$10

616.8%

Low Target

$3

115.1%

Current Price

$1.40

as of today

Based on analyst price targets, the HUMA stock price prediction for the next 12 months ranges from $3 to $10. The consensus HUMA price forecast of $5.58 implies 300.0% upside from the current price of $1.40.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$1.465.00%

1-day model range: $1.44–$1.49. Peak: $1.49 (+5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$1-34.2%
2028$1-45.5%
2029$1-50.1%
2030$1-52.3%
2031-53.3%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

86%0%14%
12Buy
0Neutral
2Sell
RSI (14)73.8Overbought
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · HUMA · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$1.41SELL
MA 10$1.33BUY
MA 20$1.15BUY
MA 50$0.91BUY
MA 100$0.98BUY
MA 200$1.21BUY
Current $HUMA · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$1.38BUY
EMA 10$1.32BUY
EMA 20$1.20BUY
EMA 50$1.05BUY
EMA 100$1.06BUY
EMA 200$1.35BUY
Current $HUMA · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Benchmark2026-06-01
Maintains
Speculative BuySpeculative Buy
HC Wainwright & Co.2026-05-26
Maintains
BuyBuy
TD Cowen2026-05-14
Maintains
BuyBuy
BTIG2026-05-13
Maintains
BuyBuy
BTIG2026-04-28
Maintains
BuyBuy
D. Boral Capital2026-04-28
Maintains
BuyBuy
D. Boral Capital2026-04-24
Maintains
BuyBuy
D. Boral Capital2026-04-21
Maintains
BuyBuy
Barclays2026-04-08
Maintains
OverweightOverweight
Benchmark2026-03-31
Maintains
BuySpeculative Buy

Wall Street analysts have recently issued updated ratings on Humacyte, Inc. (HUMA) stock. Of the recent 91 rating actions, 0 were upgrades and 0 were downgrades. 11 analysts currently cover HUMA.

Analyst Recommendation Trends

Buy ratings312
Hold ratings00
Sell ratings00

HUMA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$6M

↓ 94.1% YoY

Revenue Next Year

$25M

↑ 282.3% YoY

EPS This Year

$-0.36

EPS Next Year

$-0.30

↓ 16.1% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast HUMA EPS of $-0.36 for the current fiscal year, based on estimates from 3 analysts. The HUMA revenue forecast is $6M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The HUMA stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus HUMA price target is $5.58 (+300.0% upside), with an analyst consensus of Buy.

The HUMA short-term stock prediction for tomorrow is $1.46 (+5.00%). The HUMA stock price prediction for 2027 estimates an average of $1. The HUMA stock prediction for 2030 projects a range of $1–$1.

Humacyte, Inc. trades on NASDAQ under the ticker HUMA. The HUMA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 91% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

HUMA forecast · 8 questions

According to 11 Wall Street analysts, the average 12-month HUMA price target is $5.58, with a high forecast of $10.00 and a low of $3.00. The median price target is shown in the chart above when available. This implies +300.0% potential upside from the current price of $1.40.

HUMA price targetWhat is HUMA price targetHUMA analyst price targetHUMA 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.